Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma

URN:NBN:SI:doc-XN4T2L812007Jezeršek Novaković, BarbaraJužnič Šetina, TanjaKotnik, VladimirNovaković, SrdjanVovk, Marjetadocuments/znanstveni_clanki/radiology_and_oncology/html/urn_nbn_si_doc-xn4t2l81.htmldocuments/znanstveni_clanki/radiology_and_oncology/pdf/urn_nbn_si_doc-xn4t2l81.pdfdocuments/znanstveni_clanki/radiology_and_oncology/txt/urn_nbn_si_doc-xn4t2l81.txt110 strani41articlestr. 23-321318-209922731225URN:NBN:SI:doc-XN4T2L81engAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYAntibodies, MonoclonalantigeniAntigeni, CD20Antigens, Cd20ApoptosisApoptozabiokemijaBrez bolezni, preživetjeCelica, preživetjeCell SurvivalDisease-Free SurvivalDrug EffectsDrug TherapyFlow CytometrylimfomLimfom B-celičniLymphoma, B-CellMonocitiMonocytesonkologijaPretočna citometrijaProtitelesa monoklonskatherapyzdravljenjeTesting of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma